Jazz Zeroes in on Next-Gen T Cell Engagers with AbCellera Deal

Jazz zeroes in on next-gen T cell engagers with AbCellera deal

The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of certain blood cancers.

Jazz, AbCellera sign deal for T-cell engagers in solid tumours

The collaboration involves up to $56m in upfront payments to AbCellera for the first two research programmes, with an additional $28m payable if a third programme begins within The post Jazz and AbCellera sign deal for T-cell engagers in solid tumours appeared first on Pharmaceutical Business review.

Jazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCellera - European Biotechnology Magazine

Dublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and political activist Peter Thiel. The post Jazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCellera appeared first on European Biotechnology Magazine.

Jazz turns to AbCellera for T cell engagers against GI cancers in up to $4.1B deal

For much of its first decade, Canadian antibody developer AbCellera signed partnership after partnership, securing 40 biopharma alliances that led to more than a dozen clinical-stage drug candidates. Then, in 2023 ...